Stock Traders Purchase High Volume of Call Options on DexCom (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM) was the recipient of unusually large options trading on Monday. Stock investors purchased 14,972 call options on the stock. This represents an increase of 120% compared to the typical volume of 6,802 call options.

DexCom Stock Performance

NASDAQ:DXCM traded up $4.00 during mid-day trading on Monday, reaching $68.00. 8,190,021 shares of the company’s stock were exchanged, compared to its average volume of 3,312,346. DexCom has a one year low of $62.34 and a one year high of $142.00. The firm has a market capitalization of $27.25 billion, a PE ratio of 43.45, a price-to-earnings-growth ratio of 1.58 and a beta of 1.16. The business’s fifty day simple moving average is $115.28 and its two-hundred day simple moving average is $123.76. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same period last year, the firm earned $0.34 earnings per share. DexCom’s revenue for the quarter was up 15.3% compared to the same quarter last year. Analysts anticipate that DexCom will post 1.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on DXCM shares. Morgan Stanley lowered their price objective on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research note on Friday. Raymond James upped their target price on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. Stifel Nicolaus cut their target price on shares of DexCom from $132.00 to $90.00 and set a “buy” rating on the stock in a research note on Friday. Baird R W lowered shares of DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday. Finally, UBS Group dropped their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research note on Friday. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $113.06.

Insider Buying and Selling

In related news, CFO Jereme M. Sylvain sold 745 shares of DexCom stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $85,712.25. Following the completion of the transaction, the chief financial officer now directly owns 84,948 shares in the company, valued at approximately $9,773,267.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other DexCom news, CFO Jereme M. Sylvain sold 745 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $115.05, for a total value of $85,712.25. Following the completion of the transaction, the chief financial officer now directly owns 84,948 shares in the company, valued at approximately $9,773,267.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the sale, the director now directly owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The disclosure for this sale can be found here. Insiders sold 4,112 shares of company stock worth $480,861 in the last ninety days. Insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

Several hedge funds have recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of DexCom in the 2nd quarter valued at approximately $25,000. Whittier Trust Co. boosted its stake in shares of DexCom by 3,593.8% in the 2nd quarter. Whittier Trust Co. now owns 1,182 shares of the medical device company’s stock valued at $134,000 after purchasing an additional 1,150 shares in the last quarter. Kintegral Advisory LLC acquired a new stake in shares of DexCom in the 2nd quarter valued at approximately $1,334,000. Conning Inc. boosted its position in DexCom by 11.1% during the 2nd quarter. Conning Inc. now owns 2,075 shares of the medical device company’s stock worth $235,000 after buying an additional 207 shares during the period. Finally, Simmons Bank boosted its position in DexCom by 5.6% during the 2nd quarter. Simmons Bank now owns 3,750 shares of the medical device company’s stock worth $425,000 after buying an additional 200 shares during the period. 97.75% of the stock is owned by institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.